In a press release Thursday, graphics chip specialist NVIDIA (NASDAQ: NVDA ) announced it will return an additional $1 billion to shareholders this fiscal year in the form of dividends and share buybacks.
If this seems like a lot for a company whose entire market capitalization is under $8 billion... well, that's because it is.
Is $1 billion overkill?
For those of you keeping track, however, you know this is pocket change for NVIDIA, which had $3.73 billion in cash and no debt on its balance sheet at the end of its most recent quarter. In fact, that's one reason I singled out NVIDIA just a few days ago as one of three solid dividend stocks�any investor could be happy to own.
Thursday's announcement, however, ups the ante, as it represents a massive vote of confidence that the puzzle pieces are in place for their long-term oriented efforts to succeed. As CEO Jen-Hsun Huang elaborated,�"NVIDIA's�strategies are gaining traction in the market and make us confident in our ability to continue generating cash."�
Hot High Tech Stocks To Own Right Now: Crown Media Holdings Inc.(CRWN)
Crown Media Holdings, Inc., through its subsidiary, Crown Media United States, LLC, owns, operates, and distributes pay television networks for adults and families primarily in the United States. The company operates and distributes Hallmark Channel network to approximately 87 million subscribers through approximately 5,369 cable, satellite, and other pay television distribution systems; and Hallmark Movie Channel network to approximately 45 million subscribers through approximately 2,680 cable, satellite, and other pay television distribution systems. Its networks offers a range of entertainment programming, including television series, movies, miniseries, theatricals, romances, literary classics, and contemporary stories. The company was founded in 1999 and is headquartered in Studio City, California.
Advisors' Opinion:- [By Jake Mann]
In 2015, I will be paying close attention the media sector...I have highlighted several stocks in 2014 that I thought were winners in the sector going forward with AMC Networks Inc (NASDAQ: AMCX), Discovery Communications Inc. (NASDAQ: DISCA), Starz (NASDAQ: STRZA), and Crown Media Holdings, Inc (NASDAQ: CRWN) the ones I like best.
Top 10 Sliver Companies To Own For 2014: AptarGroup Inc. (ATR)
AptarGroup, Inc. engages in the design, development, manufacture, and sale of consumer product dispensing systems in North America, Europe, Asia, and South America. The company operates in three segments: Beauty + Home, Pharma, and Food + Beverage. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, and accessories to the personal care and household markets, as well as pumps and decorative components to the fragrance/cosmetic market; and fragrance/cosmetic and personal care fine mist spray pumps, personal care lotion pumps, and continuous spray aerosol valves. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments in pharmaceutical market. The Food + Beverage segment offers dispensing and non-dispensing closures, spray pumps, and aerosol valves to the food and beverage markets. AptarGroup, Inc. sells its products through sales force, independent representatives, and distributors. The c ompany was founded in 1992 and is headquartered in Crystal Lake, Illinois.
Advisors' Opinion:- [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to AptarGroup (NYSE: ATR ) .
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on AptarGroup (NYSE: ATR ) , whose recent revenue and earnings are plotted below.
Top 10 Sliver Companies To Own For 2014: Points International Ltd (PCOM)
Points International Ltd. provides a range of e-commerce and technology services to loyalty program operators using. These services consist of a range of e-commerce services (referred as its Loyalty Currency Services) that enable the sale of loyalty currencies (such as frequent flyer miles, hotel points and credit card points), both retail and wholesale. The Company also offers a reward management Website referred to as Points.com. The majority of the Company�� loyalty program partners operate in the United States. It also has a European customer base. It has three wholly owned direct subsidiaries: Points.com Inc., Points International (UK) Limited, and Points International (U.S.) Ltd. The Company�� services are generally delivered through Web-enabled e-commerce solutions. Points.com offers members of multiple loyalty programs the ability to track and manage their loyalty currencies. Advisors' Opinion:- [By Hank Coleman]
Anna Subbotina/Shutterstock You may not be fully aware of it, but you're probably sitting on your own personal treasure hoard: a stash of airline miles, hotel points or reward points you've earned through your credit cards. According to statistics compiled by Points.com and its parent Points International (PCOM), a company specializing in helping consumers trade, exchange and redeem reward points, the average American is hoarding more than 61,000 reward points through various programs. Americans have more than 2.65 billion loyalty memberships -- almost 10 per person. This would be fine if we were spending those points -- but we're not. According to Points.com, only 16 percent of us redeem the points that we earn each year. Why do we love reward points? Is there a danger in hoarding them? What should we do with our points as our balances continue to grow? Why Do We Love Reward Points So Much? Getting something for free is a big allure of reward points and loyalty programs. I love that my airline-branded credit card allows me to check a bag for free. Companies view reward programs as marketing by gamification. If businesses can make patronizing them into a game for their customers, they'll be more likely to do what it takes to advance to the next level. And of course, these programs inspire brand loyalty. I'm a huge fan of Fitbit. I'm always striving for the next badge or level with my fitness goals through the site and its devices. I'm also addicted to checking in to the places that I frequent on Foursquare. It drives me crazy when someone ousts me as the mayor of one of my favorite haunts. Gamification is going on with reward points themselves. Companies have found that we desperately want to get to the next level of rewards. That's why companies have different colored credit cards and exclusive levels that offer even more freebies to loyal customers -- though usually for a price. And we are dreamers. We dream that our frequent flyer miles and hotel rew
Top 10 Sliver Companies To Own For 2014: Tesco PLC (TSCDY)
Tesco PLC, incorporated on November 27, 1947, is engaged in retailing and associated activities in the United Kingdom, China, the Czech Republic, Hungary, the Republic of Ireland, India, Malaysia, Poland, Slovakia, South Korea, Thailand and Turkey. The Company also provides retail banking and insurance services through its subsidiary, Tesco Bank. The Company�� operations in the United Kingdom is the within the Company, with over 3,000 stores. The Company�� in-store picking model is complemented by a small number of specialized dotcom-only stores, which allow the Company to respond to customer demand. The Company�� Click & Collect service is a part of its multichannel offering and enables customers to pick up their shopping when and where it suits them. It has over 1,500 Click & Collect collection points for general merchandise and over 150 Grocery Drive-thrus in the United Kingdom.
The Company�� operations in India include sourcing and its service centre, as well as a franchise arrangement with Tata Group. The Company�� Hindustan Service Centre (HSC) is the global services arm for Tesco worldwide, providing business services for Tesco operations globally. Tesco HSC is engaged in creating and executing strategic initiatives covering information technology (IT), Financial, Commercial and Property, among others. The Company also provides 80% of the stock sold by Star Bazaar, both food and non-food, sourced through its distribution centre in Mumbai. This distribution centre also provides wholesale products to traditional Indian retailers, kirana stores, restaurants and other businesses, providing small farmers and other suppliers with a way to sell their wares to the local market.
The Company has an online business and 22 of virtual stores in South Korean subways and bus stops, which help time-pressed customers, shop on-the-go using their smartphones. Tesco Lotus is its international business, serving over 11 million customers every week in over 1,400 stores. Tesco Bank! offer a range of simple personal banking products, principally-mortgages, credit cards, personal loans, and savings.
Advisors' Opinion:- [By Kevin Godbold]
So, this series aims to identify appealing FTSE 100 investment opportunities, and today ,I'm looking at Tesco (LSE: TSCO ) (NASDAQOTH: TSCDY ) , the well-known supermarket chain.
- [By Sara Sjolin]
Shares of Tesco PLC (UK:TSCO) � (TSCDY) �lost 3.5% after J.P. Morgan Cazenove cut the food retailer to underweight from neutral.
- [By Roland Head]
Today, I'm going to take a look at the PE10 for�Tesco� (LSE: TSCO ) (NASDAQOTH: TSCDY ) .
Tesco keeps getting cheaper
Tesco's share price is down by more than 9% from its mid-May peak, although the FTSE 100 has only fallen by 5.9%. Tesco's underperformance is mainly due to a downbeat interim statement last week, which showed that U.K. like-for-like sales fell by 1% in the first quarter of this year.
Top 10 Sliver Companies To Own For 2014: BioTime Inc (BTX)
BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.
HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.
The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.
Human Embryonic Stem Cell Lines for Research Use
Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.
The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.
Human Embryonic Progenitor Cells
Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.
Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.
hES Cells Carrying Genetic Diseases
The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).
ESpan Cell Growth Media
The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.
ESpy Cell Lines
The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.
HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices
HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX ) has received the dreaded one-star ranking.
- [By John Udovich]
Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:
Top 10 Sliver Companies To Own For 2014: Rent-A-Center Inc.(RCII)
Rent-A-Center, Inc., together with its subsidiaries, primarily engages in leasing household durable goods to customers on a rent-to-own basis. The company?s stores offer durable products, such as consumer electronics, appliances, computers, and furniture and accessories under flexible rental purchase agreements that allow the customer to obtain ownership of the merchandise at the conclusion of an agreed upon rental period. It also provides merchandise on an installment sales basis in its stores. As of December 31, 2010, the company operated 3,008 company-owned stores in the United States, and in Canada, Puerto Rico, and Mexico, including 42 retail installment sales stores under the names ?Get It Now? and ?Home Choice?; and 18 rent-to-own stores located in Canada under the ?Rent-A-Centre? name. It also operates 209 franchised rent-to-own stores in 32 states under the ColorTyme trade name; and 384 kiosk locations under the ?RAC Acceptance? model. In addition, the company, th rough its ColorTyme?s franchised stores, offers custom rims and tires for sale or rental under the trade names ?RimTyme? or ?ColorTyme Custom Wheels?. Rent-A-Center, Inc. was founded in 1986 and is headquartered in Plano, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Rent-A-Center (NASDAQ: RCII) were down 21.51 percent to $24.51 on Q4 results.Apple (NASDAQ: AAPL) shares tumbled 7.80 percent to $507.55 after the company issued weak sales forecast for the second quarter and reported downbeat holiday iPhone sales.
- [By Grace L. Williams]
Rent-A-Center (RCII) grabbed our attention when the new CFO joined a director for a cluster buy. Most notable were Guy Constant, who bought 10,000 shares for $248,400 and J.V. Lentell, a director, who bought 5,000 shares for $119,000. InsiderScore notes that the buys occurred in the wake of a three-year low at the rent-to-own durable goods retailer.
- [By Marc Bastow]
Rent-to-own consumer products company Rent-A-Center (RCII) raised its quarterly dividend 10% to 23 cents per share, payable on Jan. 23 to shareholders of record as of Jan. 3.
RCII Dividend Yield: 2.77% - [By Garrett Cook]
Rent-A-Center (NASDAQ: RCII) shares tumbled 12.42 percent to $25.45 after the company issued a downbeat guidance for the second quarter. The company expected adjusted earnings of $0.36 to $0.38 per share on revenue of around $773 million.
Top 10 Sliver Companies To Own For 2014: Cardiovascular Systems Inc.(CSII)
Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing minimally invasive treatment solutions for vascular disease. Its primary products include catheter-based platforms, such as the Diamondback 360�PAD System, the Diamondback Predator 360�PAD System, and Stealth 360�PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The PAD Systems consists of a single-use catheter that travels over its proprietary ViperWire guidewire and are used in conjunction with a reusable external control unit or a saline infusion pump. It markets and sells its products through direct sales force to hospitals and office based laboratories in the United States. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.
Advisors' Opinion:- [By Todd Campbell]
So far I've outlined the reasons for the robust returns last year at diabetes device maker Dexcom and cardiovascular device play Cardiovascular Systems (NASDAQ: CSII ) . That brings us to No. 3 in my series,�Abiomed (NASDAQ: ABMD ) , a company that saw its latest product line propel its shares 98% higher in 2013.
- [By James Oberweis]
Cardiovascular Systems, Inc. (CSII) sells devices (called atherectomy devices) that remove the plaque altogether versus traditional angioplasty devices that push the plaque into the vessel.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company Cardiovascular Systems (NASDAQ: CSII ) has received a distressing two-star ranking.
No comments:
Post a Comment